Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.


Study Finds That Only Half Of A Commonly Used Cancer Drug Is Activated In Cancer Patients 

NEW ORLEANS, June 8, 2004 According to results reported at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO), only half of the delivered dose of a commonly used chemotherapeutic agent may be activated in cancer patients.

The study, presented in a poster discussion session by Jason Fisher, a student at the University of Pittsburgh School of Engineering, analyzed data from 31 cancer patients given 30-minute infusions of gemcitabine to determine what percentage of the drug dose was associated with concentrations that exceeded the body's ability to activate the drug. He found that while approximately 50 percent of the gemcitabine dose was likely to be converted to active metabolites, the other 50 percent was likely to be inactivated, and as a result, possibly not contribute to a therapeutic effect.

The purpose of this study was to use mathematics and engineering to try to improve cancer therapy, said Robert Parker, Ph.D., assistant professor of chemical engineering at the University of Pittsburgh and Mr. Fishers undergraduate research project advisor. We were surprised to find that about half of the dose of the drug administered might not be converted into an active form. The implication is that alternative schedules of gemcitabine infusions need to be evaluated carefully.

Dr. Parker explained that patients received gemcitabine doses of 650-950 mg/square meter and underwent pharmacokinetic sampling. Mathematical models were developed to calculate the time profile of drug concentrations in the body. Although the study results demonstrate that administering gemcitabine as a 30-minute infusion resulted in approximately half of the dose being inactivated before it could be metabolized, the clinical implications of the data need to be explored further, said Dr. Parker.

The study was conducted on behalf of the Cancer and Leukemia Group B. Co-investigators of the study include Merrill J. Egorin, M.D., professor of medicine and pharmacology, University of Pittsburgh Cancer Institute; Mark J. Ratain, M.D., professor of medicine, University of Chicago; and Alan Venook, M.D., professor of medicine, University of California San Francisco. Support for the study was provided by Eli Lilly and Company.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |